Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Ascentia Biomedical Corporation has acquired an option from the University of Washington for a family of novel, powerful compounds to be developed for the treatment of serious human diseases.
Subscribe to our email newsletter
According to the company one of these compounds has already shown repeated efficacy in blocking tumors in a pre-clinical model of breast cancer. Other compounds in the family have also undergone pre-clinical testing and will be developed in indications such as sepsis (a life-threatening condition caused by infection), autoimmune disorders such as arthritis, and as a drug enhancing agent for various vaccines.
Ascentia’s scientific team plans to quickly conduct further testing of the lead compound for cancer treatment in an effort to file it as an investigational new drug (IND) with the FDA.
Dr James Clagett, president and CEO of Ascentia said, “We are pleased and excited to have an option agreement for these important compounds from the University of Washington which show great promise as future drugs for serious and life-threatening diseases which affect millions. Cleary, these compounds will be a significant addition to Ascentia’s drug development program.”